- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01778179
A Fixed Triple Combination Cream for Solar Lentigines Associated to Cryotherapy
Safety and Efficacy of a Triple Combination Cream as Adjuvant Treatment of Solar Lentigines With Cryotherapy.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
To evaluate safety and efficacy of Tri-Luma® cream as an adjunctive treatment to cryotherapy when used in the pre- and post-procedure phases for the treatment of solar lentigines on the back of the hands and in the prevention of post-inflammatory hyperpigmentation after cryotherapy.
The study has 13 weeks for each subject. Five visits will take place: at Baseline, week 2, 5, 9 and 13 after the cryotherapy.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subject agreement to provide written informed consent and the willingness and ability to comply with all aspects of the protocol;
- Female and male subjects;
- Phototype II to IV;
- Subjects aged between 40 and 65 years;
- Subjects presenting at least 5 lesions of solar lentigines at the back hands with al least 3mm of diameter
- History of post-inflammatory hyperpigmentation on body or face
- Medical history and physical examination which, based on the investigator's opinion, do not prevent the subject from taking part in the study or from making use of the products under investigation;
- Subjects of childbearing age should present a negative urine pregnancy test at baseline and should be using a highly effective contraceptive method during all study;
- Availability of the subject throughout the study;
- Subject agreeing not to undergo other cosmetic or dermatological procedures during the participation in the study;
- Subjects with sufficient schooling and knowledge to enable them to cooperate to the degree required by the protocol.
Exclusion Criteria:
- Pregnant women or women intending to become pregnant in the following 5 months after screening;
- Lactation period;
- Subjects participating in other clinical trials;
- Any prior cosmetic procedures, including fillers, or scars that may interfere with the study results;
- Subjects with neoplastic, muscular or neurological diseases;
- Subjects with inflammation or active infection in the area to be studied;
- Subjects with a history of adverse effects, such as sensitivity to the components of any of the study drug formula,
- Subjects with a history of non-adherence to medical treatment or showing unwillingness to adhere to the study protocol;
- Any condition that, in the opinion of the investigator, can compromise the evaluation of the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Group 1
Subjects (group 1) will be treated daily for their solar lentigines with the investigational drug (Tri-Luma® cream) plus sunscreen for 2 weeks. At week 2, all the subjects will have the solar lentigines treated by cryotherapy (CRY-AC3® device). Post-procedure phase (From Week 2 up to Week 13)
The investigational drug (Tri-Luma® cream) plus sunscreen will be applied again (group 1) for a minimum of 4 weeks and up to 8 weeks, according to the Global Improvement of solar lentigines and absence of PIH. |
Pre-procedure phase (From Baseline up to Week 2) treated daily for their solar lentigines with the investigational drug (Tri-Luma® cream) for 2 weeks. Post-procedure phase (From week 2 up to Week 13 - Visit ) - Tri-Luma® cream treatment phase (from week 5 up to week 13 - visit 3 up to visit 5):The investigational drug (Tri-Luma® cream) will be applied again (group 1) for a minimum of 4 weeks and up to 8 weeks, according to the Global Improvement of solar lentigines and absence of PIH.
Procedure performed at week 2.
|
Placebo Comparator: Group 2
Subjects (group 2) will be treated daily for their solar lentigines with sunscreen alone for 2 weeks. At week 2, all the subjects will have the solar lentigines will treated by cryotherapy (CRY-AC3® device). Post-procedure phase (Week 2 up to Week 13)
Sunscreen alone will be applied again (group 1) for a minimum of 4 weeks and up to 8 weeks, according to the Global Improvement of solar lentigines and absence of PIH. |
Procedure performed at week 2.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Solar Lentigines Count
Time Frame: up to 13 weeks
|
Solar lentigines count up to 13 weeks
|
up to 13 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change From Baseline in Melanin Levels
Time Frame: Baseline and up to 13 weeks
|
This assessment was made using a narrowband reflectance spectrophotometer (Mexameter MX18®, Courage-Khazaka, Germany). The measurement is based on absorption/reflection. The probe of the Mexameter® MX 18 emits three specific light wavelengths. A receiver measures the light reflected by the skin. As the quantity of emitted light is defined, the quantity of light absorbed by the skin can be calculated. The melanin is measured by two specific wavelengths (red: 660 nm and near infrared: 880 nm) chosen to correspond to different absorption rates by the pigments. The quantification of melanin is presented as a value that varies from 0-999. The higher the value, the larger is the amount of melanin on the skin. |
Baseline and up to 13 weeks
|
Collaborators and Investigators
Investigators
- Principal Investigator: Doris Hexsel, MD, Brazilian Center For Studies in Dermatology
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2012-03
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Solar Lentigines
-
University of ZurichCompletedSolar LentiginesSwitzerland
-
National Taiwan University HospitalL'OrealUnknown
-
Panion & BF Biotech Inc.CompletedSolar LentiginesTaiwan
-
Shahid Beheshti University of Medical SciencesCompletedSolar LentiginesIran, Islamic Republic of
-
Cynosure, Inc.CompletedFacial Solar LentiginesUnited States
-
Mahidol UniversityCompleted
-
Zealand University HospitalCompleted
-
Laval UniversityCompleted
-
The Maas ClinicMedicis Pharmaceutical CorporationCompletedIntrinsic Aging of Skin | Solar ElastosisUnited States
Clinical Trials on Tri-luma
-
Galderma R&DCompletedMelasmaBrazil, Mexico
-
Illumicure IncUnknownPsoriasisUnited States
-
Pontificia Universidad Catolica de ChileGalderma R&DCompleted
-
Illumicure IncUnknown
-
Washington University School of MedicineCompleted
-
SpectraScienceUniversity of IowaTerminated
-
Federal University of São PauloInstituto Paulista de Estudos e Pesquisa em Oftalmologia; Eye Clinic Day Hospital...Completed
-
Pusan National University HospitalErbe USA IncorporatedRecruitingLung NoduleKorea, Republic of
-
Regional Hospital HolstebroCompleted
-
Institut de Recherche pour le DeveloppementMedical Research Council; Institut Pasteur; Centre Muraz; REVS PLUS Burkina Faso; Young Gambian Mums Fund and other collaboratorsNot yet recruiting